Analysts have revised their price target for Cohance Lifesciences down from ₹1,213 to ₹1,171. This change reflects tempered expectations for revenue growth, partially offset by stronger profit margins.
What's in the News
- The board meeting is scheduled for November 12, 2025, to consider and approve unaudited financial results for the quarter and half-year ended September 30, 2025 (company announcement).
- The company announced an INR 230 million investment in a new cGMP oligonucleotide building block manufacturing facility in Hyderabad, India. This facility will increase capacity to up to 700 kg annually and support global expansion in niche technologies (company announcement).
- The company invested USD 10 million to expand cGMP bioconjugation capabilities at its U.S. subsidiary NJ Bio, enhancing end-to-end Antibody-Drug Conjugate (ADC) manufacturing offerings and supporting clinical supply needs (company announcement).
Valuation Changes
- Fair Value Estimate has been reduced from ₹1,213 to ₹1,171, reflecting a modest decrease in projected intrinsic value.
- Discount Rate remains unchanged at 12.73%.
- Revenue Growth expectation has been lowered from 63.8% to 60.8%.
- Net Profit Margin is projected to rise slightly, from 24.17% to 24.99%.
- Future P/E Ratio has decreased marginally, from 60.68x to 59.87x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.